PURPOSE: To report the effectiveness of various forms of vision therapy/orthoptics in improving accommodative amplitude and facility in children with symptomatic convergence insufficiency (CI) and co-existing accommodative dysfunction. METHODS: In a randomized clinical trial, 221 children aged 9 to 17 years with symptomatic CI were assigned to one of four treatments. Of the enrolled children, 164 (74%) had accommodative dysfunction; 63 (29%) had a decreased amplitude of accommodation with respect to age, 43 (19%) had decreased accommodative facility, and 58 (26%) had both. Analysis of variance models were used to compare mean accommodative amplitude and accommodative facility for each treatment group after 4, 8, and 12 weeks of treatment. RESULTS: After 12 weeks of treatment, the increases in amplitude of accommodation [office-based vergence/accommodative therapy with home reinforcement group (OBVAT) 9.9 D, home-based computer vergence/accommodative therapy group (HBCVAT+) 6.7 D, and home-based pencil push-up therapy group (HBPP) 5.8 D] were significantly greater than in the office-based placebo therapy (OBPT) group (2.2 D) (p-values ≤0.010). Significant increases in accommodative facility were found in all groups (OBVAT: 9 cpm, HBCVAT+: 7 cpm, HBPP: 5 cpm, OBPT: 5.5 cpm); only the improvement in the OBVAT group was significantly greater than that found in the OBPT group (p = 0.016). One year after completion of therapy, reoccurrence of decreased accommodative amplitude was present in only 12.5% and accommodative facility in only 11%. CONCLUSIONS:Vision therapy/orthoptics is effective in improving accommodative amplitude and accommodative facility in school-aged children with symptomatic CI and accommodative dysfunction.
RCT Entities:
PURPOSE: To report the effectiveness of various forms of vision therapy/orthoptics in improving accommodative amplitude and facility in children with symptomatic convergence insufficiency (CI) and co-existing accommodative dysfunction. METHODS: In a randomized clinical trial, 221 children aged 9 to 17 years with symptomatic CI were assigned to one of four treatments. Of the enrolled children, 164 (74%) had accommodative dysfunction; 63 (29%) had a decreased amplitude of accommodation with respect to age, 43 (19%) had decreased accommodative facility, and 58 (26%) had both. Analysis of variance models were used to compare mean accommodative amplitude and accommodative facility for each treatment group after 4, 8, and 12 weeks of treatment. RESULTS: After 12 weeks of treatment, the increases in amplitude of accommodation [office-based vergence/accommodative therapy with home reinforcement group (OBVAT) 9.9 D, home-based computer vergence/accommodative therapy group (HBCVAT+) 6.7 D, and home-based pencil push-up therapy group (HBPP) 5.8 D] were significantly greater than in the office-based placebo therapy (OBPT) group (2.2 D) (p-values ≤0.010). Significant increases in accommodative facility were found in all groups (OBVAT: 9 cpm, HBCVAT+: 7 cpm, HBPP: 5 cpm, OBPT: 5.5 cpm); only the improvement in the OBVAT group was significantly greater than that found in the OBPT group (p = 0.016). One year after completion of therapy, reoccurrence of decreased accommodative amplitude was present in only 12.5% and accommodative facility in only 11%. CONCLUSIONS: Vision therapy/orthoptics is effective in improving accommodative amplitude and accommodative facility in school-aged children with symptomatic CI and accommodative dysfunction.
Authors: Eric J Borsting; Michael W Rouse; G Lynn Mitchell; Mitchell Scheiman; Susan A Cotter; Jeffrey Cooper; Marjean Taylor Kulp; Richard London Journal: Optom Vis Sci Date: 2003-12 Impact factor: 1.973
Authors: Daniel J Corwin; Mark R Zonfrillo; Christina L Master; Kristy B Arbogast; Matthew F Grady; Roni L Robinson; Arlene M Goodman; Douglas J Wiebe Journal: J Pediatr Date: 2014-09-26 Impact factor: 4.406
Authors: Anne M Menjivar; Marjean T Kulp; G Lynn Mitchell; Andrew J Toole; Kathleen Reuter Journal: Clin Exp Optom Date: 2018-03-13 Impact factor: 2.742
Authors: Kristy B Arbogast; Riddhi P Ghosh; Daniel J Corwin; Catherine C McDonald; Fairuz N Mohammed; Susan S Margulies; Ian Barnett; Christina L Master Journal: J Neurotrauma Date: 2022-10 Impact factor: 4.869
Authors: Anne Mucha; Michael W Collins; R J Elbin; Joseph M Furman; Cara Troutman-Enseki; Ryan M DeWolf; Greg Marchetti; Anthony P Kontos Journal: Am J Sports Med Date: 2014-08-08 Impact factor: 6.202
Authors: Daniel J Corwin; Mark R Zonfrillo; Douglas J Wiebe; Christina L Master; Matthew F Grady; Kristy B Arbogast Journal: Brain Inj Date: 2018-03-27 Impact factor: 2.311
Authors: Patricia R Roby; Kristina B Metzger; Catherine C McDonald; Daniel J Corwin; Colin M Huber; Declan A Patton; Susan S Margulies; Matthew F Grady; Christina L Master; Kristy B Arbogast Journal: Phys Sportsmed Date: 2021-09-21 Impact factor: 2.241
Authors: Daniel J Corwin; Catherine C McDonald; Kristy B Arbogast; Fairuz N Mohammed; Matthew F Grady; Christina L Master Journal: Clin J Sport Med Date: 2021-06-22 Impact factor: 3.454